ReviewOrthopaedic journal of sports medicine2026
Poor Adherence to Minimum Information for Studies Evaluating Biologics in Orthopaedics Guidelines: Platelet-Rich Plasma-Augmented ACL Reconstruction.
Review in Orthopaedic journal of sports medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Background: Platelet-rich plasma (PRP) has gained widespread use an adjunct to orthopaedic procedures, yet clinical studies have reported conflicting efficacy. The Minimum Information for Studies Evaluating Biologics in Orthopaedics (MIBO) guidelines were published in 2017 to standardize reporting of PRP preparation, characterization, and delivery, which may explain the heterogeneity of clinical outcomes in studies evaluating PRP for anterior cruciate ligament reconstruction (ACLR). Purpose: To evaluate adherence to MIBO guidelines in studies evaluating PRP-augmented ACLR and to assess whether reporting adherence improved after the publication of the 2017 guidelines. Study Design: Systematic review; Level of evidence, 3. Methods: A systematic literature search was conducted using the PubMed/MEDLINE, Embase, and Web of Science databases in March 2025 to identify studies evaluating PRP-augmented ACLR. Included studies were randomized controlled trials (RCTs), prospective and retrospective cohort studies, and case-control studies published in the English language. Two independent reviewers extracted data on study characteristics and assessed adherence to all 23 MIBO checklist items. Results: A total of 26 studies (14 RCTs, 12 observational studies) involving 1319 patients were included. The mean MIBO adherence was 40.1% (9.2/23 items) for pre-MIBO studies and 50.1% (11.5/23 items) for post-MIBO studies, with no statistically significant improvement ( Conclusion: Adherence to the 2017 MIBO guidelines in studies evaluating PRP-augmented ACLR remains poor, with no significant improvement after guideline publication. Critical information regarding PRP preparation, characterization, and platelet recovery rate continues to be inadequately reported, limiting study reproducibility and the ability to determine true PRP efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.